These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35979920)

  • 1. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice.
    Cantarelli L; Pestana Grafiña D; Gonzalez Perez A; García Gil S; Gutiérrez Nicolás F; Ramos Santana E; Navarro Dávila MA; Otazo Pérez SM; Calzado Gómez G; Perez Reyes S; Nazco Casariego GJ
    Ann Pharmacother; 2023 Apr; 57(4):416-424. PubMed ID: 35979920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
    Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
    J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 7. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
    Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
    Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
    Silberstein SD; Reshef S; Cohen JM; Gandhi S; Seminerio M; Ramirez Campos V; Kessler Y; Thompson SF; Blumenfeld A
    Adv Ther; 2023 Feb; 40(2):445-459. PubMed ID: 36350532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Vig SJ; Garza J; Tao Y
    Headache; 2022 Nov; 62(10):1256-1263. PubMed ID: 35467013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
    Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
    J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.
    Gantenbein AR; Agosti R; Kamm CP; Landmann G; Meier N; Merki-Feld GS; Petersen JA; Pohl H; Ryvlin P; Schankin CJ; Viceic D; Zecca C; Schäfer E; Meyer I; Arzt ME
    J Headache Pain; 2022 Nov; 23(1):142. PubMed ID: 36401172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials.
    Masoud AT; Hasan MT; Sayed A; Edward HN; Amer AM; Naga AE; Elfil M; Alghamdi BS; Perveen A; Ashraf GM; Bahbah EI
    J Neurol Sci; 2021 Aug; 427():117505. PubMed ID: 34082147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.